{
    "clinical_study": {
        "@rank": "153209", 
        "arm_group": {
            "arm_group_label": "Oshadi treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study will be a prospective open-label single-center study in previously treated\n      patients with Non Small Cell Lung Cancer (NSCLC). Treatment efficacy and safety of the\n      combination of Oshadi D and Oshadi R with Docetaxel will be will be evaluated.\n\n      Patients will receive Docetaxel in combination with Oshadi D and Oshadi R. Patient will be\n      evaluated throughout the study for safety and tolerance to multiple dose regimens of Oshadi\n      D and Oshadi R.\n\n      CT or MRI imaging will be performed prior to treatment initiation and at the end of every 3\n      Docetaxel cycles (12 weeks). In case of disease progression, dose augmentation will be\n      considered or subsequent therapy."
        }, 
        "brief_title": "Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced or metastatic NSCLC (IIIB-IV)\n\n          -  Failure of first line anti-cancer therapy (either radiological documentation of\n             disease progression or due to toxicity) in advanced disease or subsequent relapse of\n             disease following first line therapy\n\n          -  Man or woman 21 years and above\n\n          -  Adequate performance status (ECOG 0, and 1)\n\n          -  Patient must have adequate organ function\n\n          -  Written informed consent\n\n          -  Females of childbearing potential and males must be willing to use an effective\n             method of contraception (hormonal or barrier method of birth control; abstinence)\n             from the time consent is signed until 6 weeks after treatment discontinuation.\n\n          -  Females of childbearing potential must have a negative pregnancy test within 7 days\n             prior to being registered for protocol therapy.\n\n        Exclusion Criteria:\n\n          -  Any treatment with investigational agent within 10 days prior to registration for\n             protocol therapy.\n\n          -  Cerebrovascular accident, transient ischemic attack or myocardial infarction within 3\n             months prior to registration for protocol therapy.\n\n          -  Evidence of pulmonary embolism within 3 months prior to registration for protocol\n             therapy.\n\n          -  Any history of hematologic malignancies.\n\n          -  Patient with known positive HIV serology at screening.\n\n          -  Female patient who are breastfeeding or have a positive pregnancy test at screening\n             or at any time during the study.\n\n          -  Uncontrolled hypertension (>160/100 mm Hg despite optimal medical therapy).\n\n          -  Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for\n             Adverse Effects) Version 3.0 grade 2.\n\n          -  Patients in whom radiation or surgery is indicated\n\n          -  Significant swallowing disorders.\n\n          -  Small bowel surgery.\n\n          -  Suspicion of absorption disruption as a result of abdominal radiation\n\n          -  Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical\n             situation which could affect oral absorption.\n\n          -  Evidence of concurrent (< 5 years) second malignancy\n\n          -  Mental disorders.\n\n          -  Inability to give written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134990", 
            "org_study_id": "OS-LC-P2a-01"
        }, 
        "intervention": {
            "arm_group_label": "Oshadi treatment", 
            "description": "Anti cancer agents", 
            "intervention_name": "Oshadi D and Oshadi R", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carcinoma, Non-Small-Cell Lung", 
            "Docetaxel"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "hanna@oshadi-da.com", 
                "last_name": "Hanna Levy, Dr.", 
                "phone": "+972-52-2824966"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel"
                }, 
                "name": "Hadassah Medical Center"
            }, 
            "investigator": {
                "last_name": "Hovav Nehushtan, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "hanna@oshadi-da.com", 
            "last_name": "Hanna Levy, Dr.", 
            "phone": "+972-52-2824966"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medical Center", 
            "last_name": "Hovav Nehushtan, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall survival time", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134990"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse events and serious adverse events occurence", 
            "safety_issue": "Yes", 
            "time_frame": "One month following treatment initiation"
        }, 
        "source": "Oshadi Drug Administration", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oshadi Drug Administration", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}